PPA
CBAY

Parametric Portfolio Associates’s Cymabay Therapeutics CBAY Stock Holding History

Parametric Portfolio Associates’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$1.04M Buy
334,713
+95,698
+40% +$301K ﹤0.01% 2766
2021
Q4 		$808K Buy
239,015
+2,258
+1% +$8.57K ﹤0.01% 2867
2021
Q3 		$864K Buy
236,757
+21,817
+10% +$86K ﹤0.01% 2865
2021
Q2 		$937K Sell
214,940
-88,939
-29% -$394K ﹤0.01% 2799
2021
Q1 		$1.38M Sell
303,879
-240,146
-44% -$1.29M ﹤0.01% 2997
2020
Q4 		$3.12M Sell
544,025
-7,233
-1% -$54.8K ﹤0.01% 2384
2020
Q3 		$3.99M Sell
551,258
-25,460
-4% -$136K ﹤0.01% 2050
2020
Q2 		$2.01M Buy
576,718
+404,078
+234% +$1.17M ﹤0.01% 2501
2020
Q1 		$256K Buy
172,640
+57,663
+50% +$96.8K ﹤0.01% 3446
2019
Q4 		$225K Sell
114,977
-66,543
-37% -$250K ﹤0.01% 3698
2019
Q3 		$929K Buy
181,520
+151,682
+508% +$918K ﹤0.01% 3063
2019
Q2 		$214K Buy
29,838
+4,920
+20% +$55.7K ﹤0.01% 3721
2019
Q1 		$331K Buy
24,918
+9,316
+60% +$99.1K ﹤0.01% 3515
2018
Q4 		$123K Buy
+15,602
New +$149K ﹤0.01% 3759
2018
Q2 		– Sell
-122,984
Closed -$1.6M – 3952
2018
Q1 		$1.6M Sell
122,984
-14,099
-10% -$175K ﹤0.01% 2759
2017
Q4 		$1.26M Sell
137,083
-7,822
-5% -$66.8K ﹤0.01% 2893
2017
Q3 		$1.17M Buy
+144,905
New +$980K ﹤0.01% 2944

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

Parametric Portfolio Associates's CBAY Position: Q1 2022 in Review

Parametric Portfolio Associates increased its Cymabay Therapeutics (CBAY) stake by 40% in Q1 2022, buying an estimated $301K and bringing the position to 334,713 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #2766.

Parametric Portfolio Associates first reported a position in CBAY in Q3 2017 and has held it in 17 quarters since. The position peaked at $3.99M in Q3 2020. 118 funds tracked by Wall St. Rank hold CBAY as of Q1 2022.

  • Parametric Portfolio Associates held 334,713 shares of Cymabay Therapeutics worth $1.04M as of Q1 2022.
  • Parametric Portfolio Associates bought 95,698 Cymabay Therapeutics shares in Q1 2022, an estimated $301K.
  • Cymabay Therapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2766 holding.
  • Parametric Portfolio Associates first reported a position in Cymabay Therapeutics in Q3 2017 and has held it in 17 quarters since.
  • Parametric Portfolio Associates's Cymabay Therapeutics position peaked at $3.99M in Q3 2020.
  • 118 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.